Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer.
(2021) European Urology — Vol. 79, n° 2, p. 170-172 (2021)
Files
Details
- Authors
- Abstract
- The recent CARD study has shown that sequential use of androgen receptor (AR)-targeted therapies is associated with worse outcomes when compared with cabazitaxel chemotherapy. Here we argue that this accounts for the majority of patients previously treated with an AR-targeted agent.
- Affiliations
Citations
de Wit, R., Tombal, B., & Freedland, S. (2021). Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer. European Urology, 79(2), 170-172. https://doi.org/10.1016/j.eururo.2020.10.016 (Original work published 2021)